Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly gross margin; no daily interpolation. Q4 FY2025 (2025-12-31): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 782 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
NeuroSense Therapeutics Ltd.
Market Cap
$6.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.99M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
Market Cap
$7.00M
Gross Margin
54.43%
TTM Avg
58.30%
3Y Avg
57.46%
5Y Avg
45.97%
Market Cap
$6.78M
Gross Margin
64.28%
TTM Avg
69.38%
3Y Avg
65.33%
5Y Avg
71.21%
Market Cap
$7.07M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
Market Cap
$6.74M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
Market Cap
$6.62M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $6.91M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | 80.62% | 90.31% | -419.28% | -4158.68% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | 54.43% | 58.30% | 57.46% | 45.97% |
| Exicure, Inc. (XCUR)vs › | $6.82M | 0.00% | 50.00% | 48.39% | 33.40% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.78M | 64.28% | 69.38% | 65.33% | 71.21% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | 0.00% | 0.00% | 4.26% | 4.26% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -291.27% | -237.54% | -120.88% | -89.07% |
| KALA BIO, Inc. (KALA)vs › | $7.12M | 0.00% | 0.00% | 8.55% | 24.65% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.42M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
